• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Xenikos - Articles and news items

epr-logo

Xenikos’ T-Guard trial doses final patient with acute graft-versus-host disease

Industry news / 21 September 2016 / Niamh Louise Marriott, Digital Content Producer

T-Guard has been shown to be well tolerated, with a manageable side effect profile and no severe infusion reactions in patients with acute GVHD…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +